ARGX argenx SE Stock Quote

ARGX [NASD]

Healthcare | Biotechnology | Netherlands

Index	-	P/E	-	EPS (ttm)	-7.00	Insider Own	-	Shs Outstand	52.81M	Perf Week	-5.22%
Market Cap	14.58B	Forward P/E	-	EPS next Y	-18.85	Insider Trans	-	Shs Float	50.94M	Perf Month	-1.24%
Income	-367.70M	PEG	-	EPS next Q	-4.45	Inst Own	55.70%	Short Float	1.97%	Perf Quarter	-18.00%
Sales	478.90M	P/S	30.45	EPS this Y	-176.00%	Inst Trans	-0.24%	Short Ratio	5.66	Perf Half Y	-1.04%
Book/sh	28.68	P/B	9.63	EPS next Y	-85.60%	ROA	-	Target Price	350.41	Perf Year	4.00%
Cash/sh	-	P/C	-	EPS next 5Y	35.00%	ROE	-	52W Range	248.21 - 382.15	Perf YTD	-6.12%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-25.00%	52W High	-27.38%	Beta	0.90
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	11.81%	ATR	9.44
Employees	336	Current Ratio	-	Sales Q/Q	-90.00%	Oper. Margin	-24.60%	RSI (14)	35.56	Volatility	3.18% 2.80%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-4.90%	Profit Margin	-44.00%	Rel Volume	2.35	Prev Close	276.10
Shortable	Yes	LT Debt/Eq	-	Earnings	Oct 28 BMO	Payout	-	Avg Volume	177.23K	Price	277.52
Recom	2.10	SMA20	-8.35%	SMA50	-7.55%	SMA200	-8.43%	Volume	251,266	Change	0.51%

Nov-29-21

Upgrade

Piper Sandler

Neutral → Overweight

$250 → $354

Oct-29-21

Upgrade

Guggenheim

Neutral → Buy

$330

Oct-28-21

Upgrade

Raymond James

Outperform → Strong Buy

$390

Oct-07-21

Initiated

Jefferies

Buy

$362

Sep-23-21

Upgrade

Redburn

Neutral → Buy

Sep-07-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$351

Jul-23-21

Initiated

Deutsche Bank

Hold

Jul-19-21

Resumed

Wolfe Research

Outperform

Jun-18-21

Initiated

UBS

Buy

$390

Jun-04-21

Resumed

Robert W. Baird

Outperform

$340 → $346

May-10-21

Upgrade

H.C. Wainwright

Neutral → Buy

$320 → $400

Apr-23-21

Initiated

Redburn

Neutral

Mar-05-21

Reiterated

H.C. Wainwright

Neutral

$265 → $320

Feb-02-21

Downgrade

Piper Sandler

Overweight → Neutral

$303

Jan-04-21

Downgrade

Guggenheim

Buy → Neutral

Aug-25-20

Initiated

Raymond James

Outperform

$257

Aug-19-20

Downgrade

Evercore ISI

Outperform → In-line

Jul-29-20

Initiated

H.C. Wainwright

Neutral

$272

Feb-10-20

Initiated

BofA/Merrill

Buy

Nov-05-19

Initiated

Credit Suisse

Neutral

$137

Nov-10-21 01:00AM	argenx to Present at Upcoming Investor Conferences GlobeNewswire
Oct-28-21 01:00AM	argenx Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Oct-21-21 01:00AM	argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021 GlobeNewswire
Oct-18-21 05:38AM	Where Do Hedge Funds Stand On argenx SE (ARGX)? Insider Monkey
Oct-08-21 01:00AM	argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings GlobeNewswire
Sep-27-21 07:53AM	Medicines Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations. Barrons.com
Sep-24-21 07:51PM	Medicines Golden Age Is Dawning. 10 Ways to Invest Barrons.com
Sep-06-21 01:26PM	Artisan Partners: Argenx (ARGX) Could Solidify a Dominate Market Position Insider Monkey
Sep-03-21 01:00AM	argenx to Present at Upcoming Investor Conferences GlobeNewswire
Aug-25-21 01:00AM	argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis GlobeNewswire
Aug-04-21 01:00AM	argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference GlobeNewswire
Jul-29-21 01:00AM	argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update GlobeNewswire
Jul-22-21 01:00AM	argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021 GlobeNewswire
Jul-14-21 01:00AM	argenx to Host Virtual R&D Day on July 20, 2021 GlobeNewswire
Jul-13-21 10:15AM	Do Hedge Funds Love argenx SE (ARGX)? Insider Monkey
Jun-16-21 06:30PM	Argenx's drug effective against muscle-weakening disease myasthenia gravis Reuters
06:30PM	argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology GlobeNewswire
Jun-15-21 08:17AM	This Biotech Stock Has Big Potential Barrons.com
06:00AM	Argenx Is a Biotech Stock With Big Potential Barrons.com
Jun-09-21 03:53PM	Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More Zacks +8.42%
Jun-08-21 11:09AM	argenx (ARGX) to Regain AML Candidate After J&J's Dismissal Zacks
Jun-07-21 09:13AM	Argenx to Regain Worldwide Rights to Cusatuzumab from Janssen SmarterAnalyst
01:00AM	argenx to regain global rights to cusatuzumab GlobeNewswire
Jun-01-21 04:01AM	argenx Appoints Karl Gubitz as Chief Financial Officer GlobeNewswire
01:00AM	argenx to Present at Upcoming Investor Conferences GlobeNewswire
May-15-21 11:30AM	argenx SE (ARGX) Q1 2021 Earnings Call Transcript Motley Fool
May-14-21 06:45AM	argenx SE to Host Earnings Call ACCESSWIRE
01:00AM	argenx Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
May-11-21 05:00AM	argenx announces results of Annual General Meeting of Shareholders GlobeNewswire
May-10-21 11:30PM	Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript Motley Fool
May-07-21 01:00AM	argenx to Report First Quarter 2021 Financial Results and Business Update on May 14, 2021 GlobeNewswire
Apr-28-21 01:00AM	argenx Management to Present at Upcoming Virtual Investor Conferences GlobeNewswire
Mar-30-21 04:00PM	argenx announces Annual General Meeting of Shareholders on May 11, 2021 GlobeNewswire
Mar-04-21 12:30PM	argenx SE to Host Earnings Call ACCESSWIRE -7.89%
07:16AM	argenx: Q4 Earnings Insights Benzinga
01:00AM	argenx Reports Full Year 2020 Financial Results and Provides Fourth Quarter Business Update GlobeNewswire
Mar-02-21 02:00AM	argenx Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis GlobeNewswire
Feb-25-21 01:00AM	argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021 GlobeNewswire
Feb-05-21 04:01PM	argenx announces closing of global offering GlobeNewswire
Feb-04-21 01:00AM	argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
Feb-02-21 10:15PM	argenx raises $1.0 billion in gross proceeds in a global offering GlobeNewswire
09:37AM	argenx Issues Statement Concerning Efgartigimod GlobeNewswire
08:05AM	The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga
Feb-01-21 04:01PM	argenx announces launch of proposed global offering GlobeNewswire +8.32%
01:00AM	argenx Announces GO Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis GlobeNewswire
Jan-08-21 01:00AM	argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline GlobeNewswire
Jan-07-21 08:20AM	The Daily Biotech Pulse: CureVac COVID-19 Vaccine Deal, Argenx Out-Licenses Neuromuscular Disorder Drug, Xencor's Oncology Collaboration Benzinga
Jan-06-21 04:01PM	argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China GlobeNewswire
Jan-04-21 01:00AM	argenx to Present at 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-20 09:32PM	Is ARGX A Good Stock To Buy Now According To Hedge Funds? Insider Monkey
Dec-14-20 10:12AM	AstraZenecas $39 Billion Takeout of Alexion Wins Tepid Wall Street Approval Barrons.com
Nov-23-20 01:00AM	argenx Enters Into Agreement To Acquire Priority Review Voucher GlobeNewswire
Nov-17-20 07:00AM	argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience PR Newswire
Nov-09-20 01:00AM	argenx to Participate in Upcoming Virtual Investor Conferences GlobeNewswire -6.04%
Nov-03-20 04:14PM	Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High Investor's Business Daily
09:52AM	Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks
Oct-22-20 12:30PM	argenx SE to Host Earnings Call ACCESSWIRE
07:16AM	Recap: argenx Q3 Earnings Benzinga
01:00AM	argenx Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Oct-15-20 01:00AM	argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020 GlobeNewswire
Oct-06-20 08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga
02:00AM	argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships GlobeNewswire
Oct-05-20 01:00AM	argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session GlobeNewswire
Sep-16-20 04:53PM	argenx SE (ARGX): Hedge Fund Interest Inching Up Insider Monkey
Sep-02-20 01:00AM	argenx Management to Present at Upcoming Virtual Investor Conferences GlobeNewswire
Aug-04-20 01:00AM	argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Jul-30-20 01:00AM	argenx reports half year 2020 financial results and provides second quarter business update GlobeNewswire -6.04%
Jul-29-20 01:46PM	Earnings Preview: argenx Benzinga
Jul-20-20 12:15PM	Did Hedge Funds Make The Right Call On argenx SE (ARGX) ? Insider Monkey
Jul-01-20 09:24AM	argenx (ARGX): Strong Industry, Solid Earnings Estimate Revisions Zacks
Jun-15-20 11:09AM	Is argenx SE (ARGX) A Good Stock To Buy? Insider Monkey
Jun-01-20 04:00PM	argenx announces closing of global offering GlobeNewswire
May-29-20 01:00AM	argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
May-28-20 12:15AM	argenx raises $750 million in gross proceeds in a global offering GlobeNewswire
May-27-20 10:08AM	Biotech Stock Roundup: REGN's Stake Buyback, INO, NVAX's Coronavirus Updates & More Zacks
10:08AM	argenx Up on Positive Data from Pivotal Efgartigimod Study Zacks
07:25AM	The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas Benzinga
May-26-20 04:01PM	argenx announces launch of proposed global offering GlobeNewswire +34.29%
12:57PM	Here's Why argenx Stock Is Soaring Today Motley Fool
01:00AM	argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis GlobeNewswire
May-14-20 03:30PM	argenx SE (ARGX) Q1 2020 Earnings Call Transcript Motley Fool
01:00AM	argenx reports first quarter 2020 financial results and provides business update GlobeNewswire
May-12-20 09:52AM	Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates Zacks
May-11-20 05:22AM	The argenx (EBR:ARGX) Share Price Gained 1374% And Shareholders Are Jubilant Simply Wall St.
May-08-20 11:46AM	7 Strong Buy Healthcare Stocks to Buy Now InvestorPlace
Mar-22-20 10:18PM	argenx SE (ARGX): Hedge Funds In Wait-and-See Mode Insider Monkey
Feb-27-20 08:09AM	Top Ranked Momentum Stocks to Buy for February 27th Zacks
01:00AM	argenx reports full year 2019 financial results and provides fourth quarter business update GlobeNewswire
Feb-26-20 08:57AM	Why Earnings Season Could Be Great for argenx (ARGX)? Zacks
Feb-09-20 03:01AM	Our Take On argenx SE's (EBR:ARGX) CEO Salary Simply Wall St.
Jan-07-20 08:40AM	These 3 Healthcare Stocks Are Set to Soar in 2020, Says Cowen TipRanks
Dec-29-19 09:40PM	Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-07-19 08:02AM	Hedge Funds Are Warming Up To argenx SE (ARGX) Insider Monkey
Nov-22-19 03:22PM	3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks
Nov-12-19 04:00PM	argenx announces closing of global offering GlobeNewswire
Nov-10-19 02:52AM	If You Had Bought argenx (EBR:ARGX) Stock Five Years Ago, You Could Pocket A 1527% Gain Today Simply Wall St.
Nov-08-19 01:00AM	argenx announces full exercise of underwriters option to purchase additional ADSs GlobeNewswire
Nov-06-19 10:45PM	argenx raises $484 million in gross proceeds in a global offering GlobeNewswire
Oct-24-19 01:00AM	argenx reports third quarter 2019 financial results and provides business update GlobeNewswire
Oct-14-19 10:14PM	Hedge Funds Are Dumping argenx SE (ARGX) Insider Monkey

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.A.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience